跳至主要内容
临床试验/NCT04688736
NCT04688736招募中2 期

A Prospective, Randomized, Double-blind Controlled Trial of Chlorpheniramine Pretransfusion Medication for Allergic Transfusion Reactions

Institute of Hematology & Blood Diseases Hospital, China4 个研究点 分布在 1 个国家目标入组 6,642 人开始时间: 2021年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
6,642
试验地点
4
主要终点
The rate of allergic-transfusion reactions

研究概览

简要总结

This is a prospective, randomized, double-blind controlled trial to evaluate the efficacy of placebo versus chlorpheniramine for the prevention of allergic transfusion reactions.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

盲法说明

Neither patients nor medical staff, including physicians and nurses participating in this study, will know the group assignment after allocation.

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18~65 years old.
  • Subject is diagnosed with hematological disorder and requires blood product (i.e. suspended red blood cells, apheresis platelets, fresh frozen plasma) transfusions.
  • Subject can fully understand and voluntarily sign informed consent forms.

排除标准

  • Subject with a history of allergic diseases.
  • Subject experienced at least 1 moderate/severe or 2 mild allergic reactions in the past.
  • Subject received glucocorticoid or allergy drugs within 24 hours before blood transfusion.
  • Subject transfused with washed RBC.
  • Received allo-HSCT transplantation before.
  • Subject with heart failure.
  • Subject suffered from sequelae of cardiovascular or cerebrovascular diseases.
  • Pregnant or nursing women.
  • Inability to understand or to follow study procedures.

研究组 & 干预措施

Placebo

Experimental

Each recruited subject will oral 8mg placebo 20 minutes before blood transfusion.

干预措施: Placebo (Drug)

Chlorpheniramine

Active Comparator

Each recruited subject will oral 8mg chlorpheniramine 20 minutes before blood transfusion.

干预措施: Chlorpheniramine (Drug)

结局指标

主要结局

The rate of allergic-transfusion reactions

时间窗: within 4 hours from the start of the transfusion

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验